Bringing the fundamentals into focus…
Back to Pacific Biosciences of California, Inc.
How Pacific Biosciences of California, Inc. stacks up
PACB · against 487 other Healthcare companies of similar size
Valuation
73/ 100
Above the middle of the pack.
Ranked #146 of 488 · scores higher than 69% of peers
Bars: peers in each 10-point band of the valuation score58 peers with a valuation score of 70–79, including PACB · Click a bar to see the companies
Why valuation scores 73?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its EBITDA yield, which is stronger than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -17.3% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -16.3% vs peer median 0.0%
- more operating profit (EBITDA) for the company's total value: stronger than 92% of peers. EBITDA yield: 16.2% vs peer median 4.0%
Metric by metric
Position: dot = PACB, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PACB | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 475 reported | -17.6% | 1.0% | 12% | 30% | |
| EBITDA yieldHigher is better · 494 reported | 16.2% | 3.7% | 92% | 50% | |
| Free cash flow yieldHigher is better · 203 reported | -17.2% | -3.6% | 19% | 20% | |
| Book yieldHigher is better · 484 reported | -4.4% | 44.7% | 3% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around PACBScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score